Efficacy and safety of Autologous Fibroblasts on Acne Scars
Phase 4
- Conditions
- Patients with moderate to severe acne scars in cheek areas by global acne scar grading systemAcne scars
- Registration Number
- TCTR20220528005
- Lead Sponsor
- Research department, Faculty of Medicine Siriraj Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients with moderate to severe acne scars in cheek areas by global acne scar grading system
Exclusion Criteria
(1) were pregnant or lactating; (2) had a history of connective tissue disorder, skin cancers, or related diseases; (3) had previous autologous fibroblast treatment; (4) had previous treatment with fillers, lasers, or energy-based devices within the last 12 months; (5) had previous treatment using transdermal drug delivery, chemical peeling or topical retinoid within the last month; or (6) had an allergy to collagen, meat and dairy products, gentamycin, amphotericin B, or related products.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acne scar depression 1-, 3-, 6-, and 12-months follow-up The decreasing of acne scars depression captured by Antera 3D imaging system
- Secondary Outcome Measures
Name Time Method Skin roughness 1-, 3-, 6-, and 12-months follow-up The degree of skin roughness captured by Antera 3D imaging system,safety 1-, 3-, 6-, and 12-months follow-up history taking and physical examination